Value Analysis for Dural Substitutes: Cost per Case, Done Honestly

A value analysis committee judges a dural substitute on its cost per case, not its unit price. That figure includes the graft opened, waste from oversizing or unused grafts, adjuncts used with it, and the cost of stocking it. Complications such as CSF leaks matter too, but a supplier should present them as context, never as a promised saving.

Distributors who bring a collagen dural graft such as DESU’s DURASHEET or DECOLL to a hospital will sooner or later face the value analysis committee. This article explains how such committees usually think about dural substitutes and how to prepare a cost-per-case discussion that is useful and honest.

What does a value analysis committee want to know?

Value analysis committees vary in structure, but most ask the same core questions about any new implant. They want to know whether there is a clinical need that existing products do not meet, what the product will cost the hospital in total, what the evidence and quality documentation say, and whether the change will disrupt clinical practice or supply.

For dural substitutes, the committee is often comparing a new product with one or more grafts already on contract. The members are not neurosurgeons, apart from the clinical champion, so the information has to be clear to supply chain managers, finance staff, nurses and quality leaders. A packet that answers their questions in plain language moves faster than one that relies on surgeon enthusiasm alone.

What goes into cost per case for a dural graft?

The unit price is only the most visible part of the cost. A complete picture includes the following elements, each of which can differ between products and between surgeons.

• The graft opened for the case, at the size actually selected.
• Waste: grafts opened and not used, and oversized grafts trimmed down heavily.
• Adjuncts used with the graft, such as sealants, according to the surgeon’s technique.
• Preparation and handling: steps needed before placement, as described in the instructions for use.
• Inventory cost: number of sizes stocked, par levels and the risk of expiry on slow-moving sizes.
• For autologous grafts, the operative time and any additional incision needed to harvest tissue.

Some of these elements are easy to measure from purchasing and OR records. Others, such as handling time, are better captured from the surgeon and scrub team during an evaluation. The committee will usually accept reasonable estimates, as long as the method is explained and the same method is used for each product.

How should avoided complications be discussed?

Complications after duraplasty, such as CSF leaks, pseudomeningocele and wound problems, can carry significant costs: additional imaging, lumbar drainage, readmission or reoperation. It is natural for a supplier to want to connect a graft with fewer complications. This is exactly where many presentations lose credibility.

Complication rates depend on the patient, the procedure, the surgeon’s technique, the closure of the overlying tissues and many other factors. No dural graft, from any manufacturer, can promise a leak-free or infection-free result. A committee will rightly discount any claim of that kind unless it is backed by robust, relevant evidence.

The honest approach is to describe complications as part of the context of the decision: they are costly, they are influenced by many factors, and the committee should prefer products that fit the surgeon’s technique and are well documented. Where the hospital tracks its own complication data, an evaluation can be designed to monitor it, without promising a particular result. For background on the clinical side, see our article on pseudomeningocele after spine or cranial surgery.

A worksheet the committee can use

The table below is a template, not a set of figures. It can be filled in with the hospital’s own data for each product under consideration, so that every option is compared on the same basis.

A distributor who offers to help complete this worksheet, rather than presenting a finished conclusion, usually earns more trust from the committee. The committee owns the numbers; the distributor supplies product facts and helps gather the data.

What product facts belong in the packet?

For DESU’s collagen dura membranes, the packet should state the documented facts clearly and without embellishment:

• Both DURASHEET and DECOLL are made from pure Type I bovine collagen and are supplied in four sizes.
• DURASHEET is usable on both surfaces and suturable; DECOLL is designed for onlay use.
• Both are ready to use and gamma sterilized.
• DESU manufactures in its own cleanrooms under an ISO 13485 quality management system, and the products carry the CE mark.
• Information on animal-origin controls under the ISO 22442 series and on biological evaluation under the ISO 10993 series can be requested from DESU.

Add the instructions for use, quality certificates and the product catalogue. If the committee requests a document the distributor does not hold, it should be requested from the manufacturer rather than improvised.

It also helps to explain, in a sentence or two, why the hospital might want this particular product. For a department whose surgeons divide between sutured and onlay techniques, the fact that both options come from one manufacturer with one documentation set is a genuine operational point. For a department that has struggled with backorders, a qualified second source may be the main argument. The committee should be able to see the reason without reading the whole packet.

How should an evaluation feed the committee?

Many committees agree to a limited evaluation before making a formal decision. The evaluation is most useful when it is designed to answer the committee’s questions, not only the surgeon’s. That means agreeing in advance on what will be measured and how it will be reported.

A practical design records, for each case, the procedure, the size opened, whether the graft was trimmed heavily or replaced, any adjuncts used and short handling comments from the surgeon and scrub nurse. At the end, the distributor compiles the records into a one-page summary for the committee, alongside the completed worksheet. Patient-identifying information stays within the hospital’s own systems.

A defined end date matters as much as the data. An evaluation that drifts on without a decision ties up stock, frustrates the champion surgeon and gives the incumbent supplier time to respond. Agree the decision meeting date at the start, and send a reminder with the summary a week before.

What are the common pitfalls?

• Comparing unit prices for different sizes as if they were equivalent.
• Ignoring waste and expiry, which can change the ranking of products.
• Presenting a clinical outcome claim without evidence that applies to the product.
• Arriving without a surgeon champion who can explain the clinical need.
• Proposing an open-ended evaluation with no defined end point or decision date.

Avoiding these pitfalls will not win every decision, but it helps ensure the product is judged fairly and the distributor is seen as a reliable partner for the next decision.

Talk to a DESU product specialist

If you are preparing a value analysis packet for DURASHEET or DECOLL and need product documentation, certificates or help structuring a cost-per-case comparison, DESU’s product specialists can support you. Write to sales@desu.tr or use the contact page to tell us about the account.